472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors
- DOI
- 10.1136/jitc-2021-sitc2021.472
- Published
- 2021-11
- Container
- Regular and Young Investigator Award Abstracts
- Publisher
- BMJ Publishing Group Ltd
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2021-sitc2021.472,
title = {472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors},
author = {Manish Patel and Drew Rasco and Melissa Johnson and Anthony Tolcher and David Sommerhalder and Omid Hamid and Alexander Chung and Lixin Li and Robert Andtbacka},
year = {2021},
journal = {Regular and Young Investigator Award Abstracts},
doi = {10.1136/jitc-2021-sitc2021.472},
url = {https://doi.org/10.1136/jitc-2021-sitc2021.472}
}RIS
TY - JOUR TI - 472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors AU - Manish Patel AU - Drew Rasco AU - Melissa Johnson AU - Anthony Tolcher AU - David Sommerhalder AU - Omid Hamid AU - Alexander Chung AU - Lixin Li AU - Robert Andtbacka PY - 2021 JO - Regular and Young Investigator Award Abstracts DO - 10.1136/jitc-2021-sitc2021.472 UR - https://doi.org/10.1136/jitc-2021-sitc2021.472 ER -
APA
Patel, M., Rasco, D., Johnson, M., Tolcher, A., Sommerhalder, D., Hamid, O., Chung, A., Li, L., & Andtbacka, R. (2021). 472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2021-sitc2021.472
Source records
- crossref · retrieved 2026-09-27T10:52:46.029Z